Public Companies
Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference
Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation…
Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Erin Lewis, Scientific Director of KGK Sciences Inc. (“KGK”), the Company’s wholly owned subsidiary, will participate at the Supply Side West Conference taking place on October 31st to November 4, 2022 in Las Vegas, NV.
Erin Lewis will participate on the “Exploring the Microbiome: Science, Innovation and Delivery” panel on November 1st at 1pm.
This session will cover:
- An exploration of the volume and nature of evidence to support health benefits
- Perspectives from the registered dietician and health care practitioner sector about how to best reach end-consumers with microbiome solutions
- Market data insights on consumer buying and delivery formats
- Innovators on the technological front lines who aim to biohack the multitude of human microbial communities and influence their impact on health and performance
Register to attend here.
About KGK Science
Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points.
About Wellbeing Digital Sciences
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.
-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics7 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Law & Regulation5 days ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics7 days ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics6 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics6 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Ketamine6 days ago
DEA poised to move cannabis to Schedule III
-
Psychedelics6 days ago
Behold! A New Mushroom Emoji Has Arrived!